EcoDrugPlus

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSPFOG00000015321
Gene Symbol: HTR5A
3 Cross references
209 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSPFOG00000017362
Gene Symbol: HTR7
1 Cross references
195 Possible Orthologues:

60s Ribosomal Protein L10a-Like

Ensembl ID : ENSPFOG00000013715
Gene Symbol: LOC103141192
3 Cross references
364 Possible Orthologues:

60s Ribosomal Protein L15

Ensembl ID : ENSPFOG00000005794
Gene Symbol: LOC103142392
3 Cross references
357 Possible Orthologues:

60s Ribosomal Protein L19

Ensembl ID : ENSPFOG00000005370
Gene Symbol: LOC103155710
4 Cross references
333 Possible Orthologues:

60s Ribosomal Protein L19

Ensembl ID : ENSPFOG00000008270
Gene Symbol: LOC103142141
3 Cross references
334 Possible Orthologues:

60s Ribosomal Protein L22

Ensembl ID : ENSPFOG00000017329
Gene Symbol: LOC103154231
3 Cross references
208 Possible Orthologues:

60s Ribosomal Protein L22-Like

Ensembl ID : ENSPFOG00000017075
Gene Symbol: LOC103134662
2 Cross references
198 Possible Orthologues:

60s Ribosomal Protein L23

Ensembl ID : ENSPFOG00000009826
Gene Symbol: LOC103133095
3 Cross references
156 Possible Orthologues:

60s Ribosomal Protein L26

Ensembl ID : ENSPFOG00000000638
Gene Symbol: LOC103144500
3 Cross references
477 Possible Orthologues:

60s Ribosomal Protein L3

Ensembl ID : ENSPFOG00000010104
Gene Symbol: LOC103144928
3 Cross references
335 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSPFOG00000003461
Gene Symbol: ARAF
3 Cross references
191 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).